HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: what can be done?

Abstract
Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) is the most common complication of endoscopic retrograde cholangiopancreatography. The incidence of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis varies substantially and is reported around 1%-10%, although there are some reports with an incidence of around 30%. Usually, PEP is a mild or moderate pancreatitis, but in some instances it can be severe and fatal. Generally, it is defined as the onset of new pancreatic-type abdominal pain severe enough to require hospital admission or prolonged hospital stay with levels of serum amylase two to three times greater than normal, occurring 24 h after ERCP. Several methods have been adopted for preventing pancreatitis, such as pharmacological or endoscopic approaches. Regarding medical prevention, only non-steroidal anti-inflammatory drugs, namely diclofenac sodium and indomethacin, are recommended, but there are some other drugs which have some potential benefits in reducing the incidence of post-ERCP pancreatitis. Endoscopic preventive measures include cannulation (wire guided) and pancreatic stenting, while the adoption of the early pre-cut technique is still arguable. This review will attempt to present and discuss different ways of preventing post-ERCP pancreatitis.
AuthorsGoran Hauser, Marko Milosevic, Davor Stimac, Enver Zerem, Predrag Jovanović, Ivana Blazevic
JournalWorld journal of gastroenterology (World J Gastroenterol) Vol. 21 Issue 4 Pg. 1069-80 (Jan 28 2015) ISSN: 2219-2840 [Electronic] United States
PMID25632179 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-Inflammatory Agents
Topics
  • Anti-Inflammatory Agents (therapeutic use)
  • Cholangiopancreatography, Endoscopic Retrograde (adverse effects, instrumentation)
  • Humans
  • Pancreatitis (diagnosis, etiology, prevention & control)
  • Risk Assessment
  • Risk Factors
  • Stents
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: